


PRODUCT INFORMATION



Pomalidomide-d₅

Item No. 25358

CAS Registry No.: 1377838-49-7
Formal Name: 4-amino-2-(2,6-dioxo-3-piperidinyl-3,4,4,5,5-d₅)-1H-isoindole-1,3(2H)-dione
MF: C₁₃H₆D₅N₃O₄
FW: 278.3
Chemical Purity: ≥98% (Pomalidomide)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₅); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Pomalidomide-d₅ is intended for use as an internal standard for the quantification of pomalidomide (Item No. 19877) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Pomalidomide-d₅ is supplied as a solid. A stock solution may be made by dissolving the pomalidomide-d₅ in the solvent of choice. Pomalidomide-d₅ is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of pomalidomide-d₅ in these solvents is approximately 15 and 10 mg/ml, respectively.

Description

Pomalidomide is an analog of thalidomide (Item No. 14610) that inhibits the E3 ligase protein cereblon (CRBN) with an IC₅₀ value of approximately 3 μM for the human recombinant CRBN-DNA damage binding protein-1 (CRBN-DDB1) complex.¹ It inhibits autoubiquitination of CRBN in HEK293T cells expressing CRBN but not those expressing a thalidomide-binding defective CRBN mutation. It inhibits proliferation of U266 myeloma cells when used at concentrations ranging from 0.1 to 10 μM. Pomalidomide also has antiangiogenic and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α, and triggering the activation of caspase-8.^{2,3} Pomalidomide (3 mg/kg per day), in combination with dexamethasone, reduces tumor growth in an H929 R10-1 lenalidomide-resistant mouse xenograft model.⁴ Formulations containing pomalidomide have been used in the treatment of multiple myeloma.

References

1. Lopez-Girona, A., Mendy, D., Miller, K., *et al. Leukemia* **26(11)**, 2326-2335 (2012).
2. Zhu, Y.X., Kortuem, K.M., and Stewart, A.K. *Leukemia and Lymphoma* **54(4)**, 683-687 (2013).
3. Latif, T., Chauhan, N., Khan, R., *et al. Exp. Dermatol. Oncol.* **1(1)**, 27 (2012).
4. Rychak, E., Mendy, D., Shi, T., *et al. Br. J. Haematol.* **172(6)**, 889-901 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM